Cowen lowered the price target for the Theravance Biopharma Inc. (NASDAQ:TBPH) stock from “an Outperform” to “a Market perform”. The rating was released on August 24, 2021. The research report from JP Morgan has initiated the stock to Overweight, with a price target set at $29. The stock was initiated by Morgan Stanley, who disclosed in a research note on June 15, 2020, to Equal-Weight and set the price objective to $30. In their research brief published May 13, 2020, Cowen analysts initiated the Theravance Biopharma Inc. stock to Outperform with a price target of $42.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Theravance Biopharma Inc. (NASDAQ:TBPH) dipped -34.79% to close Tuesday’s market session at $9.24, lower as compared to yesterday’s close. The stock price fluctuated between $9.20 and $10.44 throughout the trading session with the volume trading being 10135447 shares, which represented a significant variation when compared to the three months average volume of 431.62K shares. The firm’s stock price fluctuated -27.81% within the last five trades and -32.41% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -47.17% in the last 6 months and -44.60% was subtracted to its value over the previous 3 months. TBPH stock is trading at a margin of -30.90%, -36.06% and -47.85% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, TBPH deals in the Healthcare domain. The stock is trading -59.37 percent below its 52-week high and -26.78 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -45.76. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Theravance Biopharma Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $651.79 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 10.15 that mirrors the cost to be found for sales by the market.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 5.70 percent of Theravance Biopharma Inc. shares are owned by insiders, and 84.60 percent are held by financial institutions. WORBOYS PHILIP D, the SVP, Research & Transl Science at Theravance Biopharma Inc. (TBPH) has sold 8,829 shares of firm on Mar 09 at a price of $20.00 against the total amount of $0.18 million. In another inside trade, GRAHAM RICHARD A, SVP, Development of Theravance Biopharma Inc. (NASDAQ:TBPH) sold 7,500 shares of the firm on Dec 14 for a total worth of $0.15 million at a price of $19.47. An inside trade which took place on Dec 03, SVP, Research & Transl Science of Theravance Biopharma Inc. WORBOYS PHILIP D sold 4,246 shares of firm against total price of $76428.0 at the cost of $18.00 per share.